Unilever boosts outlook on robust first half.


Consumer goods giant Unilever boosted its full-year outlook on Tuesday, following a bumper end to the first-half.

Unilever

Source: Sharecast

The owner of Dove, Lynx and Persil, among many others, said underlying sales growth in the six months to June end had risen 4.8%, driven by robust performances in both homecare and beauty and wellbeing. Company-wide volumes sparked 4.2% and prices 0.6%.

Operating profits were 2.6% higher at €4.9bn.

Fernando Fernandez, chief executive, said there had been a "significant step-up in the second quarter", including the best volume quarter for over a decade. Underlying sales growth in the final three months of the period was 5.8%, outstripping consensus for 4.3%.

He continued: "Our power brands continued to outperform, with all business groups delivering volume-led growth. Emerging markets showed momentum - India, Indonesia and Latin America all delivered strong growth - while North America again outperformed its market."

As a result, the blue chip now expects underlying sales in the second half to rise by between 4% and 5%, led by pricing, and full-year sales growth of between 4% and 6%.

It had previously forecast full-year sales growth to come in at the bottom end of that range.

Fernandez said: "The macroeconomic environment remains uncertain, but our consistency, discipline and strong first half performance give us confidence that we are well positioned to deliver our upgraded full-year outlook."

Under company veteran Fernandez, who took the top job in March 2025, Unilever has been refocusing to become a pure-play home and personal care specialist. Its ice cream business was spun off last year, and in March it agreed to merge its food business - home to Hellman’s, Knorr and Pot Noodle - with American spice maker McCormick. The combination is poised to create a company worth around $45bn.

Fernandez said the deal was "progressing well". On track to close by mid-2027, last week McCormick confirmed it would seek a secondary listing in London for the combined business. The deal still requires regulatory approvals.

See latest RNS on Investegate


ISIN: GB00BVZK7T90
Exchange: London Stock Exchange
Sell:
5,022.00 p
Buy:
5,023.00 p
Change: 407.00 ( 8.80 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.